Medicines

Here you will find the recommendations we have made about the use of individual medicines in Lancashire.

Ustekinumab

Brand: 
NICE TA: 340
Indication: Treatment of active psoriatic arthritis - rapid review of TA 313 (NICE TA340)
Disease category: Musculoskeletal and joint diseases
Commissioning responsibility: CCG
PbR excluded: Yes

Background

Ustekinumab is recommended as an option, alone or in combination with methotrexate, for treating active psoriatic arthritis in adults only when:
• treatment with tumour necrosis factor (TNF) alpha inhibitors is contraindicated but would otherwise be considered (as described in NICE technology appraisal guidance on etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis and golimumab for the treatment of psoriatic arthritis) or
• the person has had treatment with 1 or more TNF–alpha inhibitors.

Decisions of Lancashire local decision making groups:

NHS Blackburn With Darwen CCG and NHS East Lancashire CCG NHS Blackpool CCG NHS Chorley and South Ribble CCG and NHS Greater Preston CCG NHS Fylde and Wyre CCG NHS Morecambe Bay CCG NHS West Lancashire CCG

Red

Red

Red

Red

Red

Red